| Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million |
Globe Newswire |
05/05 |
07:00 |
| Shoals Technologies Group, Inc. Reports Financial Results for First Quarter 2026 |
Globe Newswire |
05/05 |
07:00 |
| First Watch Restaurant Group, Inc. Reports Q1 2026 Financial Results |
Globe Newswire |
05/05 |
07:00 |
| BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
Globe Newswire |
05/05 |
07:00 |
| Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease Week |
Globe Newswire |
05/05 |
07:00 |
| GlobalFoundries Reports First Quarter 2026 Financial Results |
Globe Newswire |
05/05 |
07:00 |
| Editas Medicine Announces First Quarter 2026 Results and Business Updates |
Globe Newswire |
05/05 |
07:00 |
| Autolus Therapeutics to Report First Quarter 2026 Financial Results and Host Conference Call on May 14, 2026 |
Globe Newswire |
05/05 |
07:00 |
| Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates |
Globe Newswire |
05/05 |
07:00 |
| Troilus Upsizes Debt Financing Mandate for up to US$1.2 Billion |
Globe Newswire |
05/05 |
07:00 |
| OTC Markets Group Welcomes CoTec Holdings Corp. to OTCQX |
Globe Newswire |
05/05 |
07:00 |
| Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026 |
Globe Newswire |
05/05 |
07:00 |
| Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights |
Globe Newswire |
05/05 |
07:00 |
| Colliers Reports First Quarter Results |
Globe Newswire |
05/05 |
07:00 |
| Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial |
Globe Newswire |
05/05 |
07:00 |
| Presenting on Emerging Growth Conference 92 Day 1 on May 6; Register to live stream |
Globe Newswire |
05/05 |
07:00 |
| Relmada Therapeutics to Present NDV-01 Abstracts at AUA2026 |
Globe Newswire |
05/05 |
07:00 |
| The Devon Group Names Kate Achille as Chief Executive Officer |
Globe Newswire |
05/05 |
07:00 |
| Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting Topline Subcutaneous Formulation Data, Broad B-Cell Mediated Disease Opportunity, and Upcoming Data Readouts |
Globe Newswire |
05/05 |
07:00 |
| Electra Therapeutics Announces First Patient Dosed in Phase 1 Study of Ipsoprubart (ELA026) in T Cell Malignancies |
Globe Newswire |
05/05 |
07:00 |
| Axsome Therapeutics to Participate in Upcoming Investor Conferences |
Globe Newswire |
05/05 |
07:00 |
| Repligen Reports First Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance |
Globe Newswire |
05/05 |
07:00 |
| Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW) |
Globe Newswire |
05/05 |
07:00 |
| Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update |
Globe Newswire |
05/05 |
07:00 |
| NeurAxis to Host First Quarter 2026 Results and Business Update Call on Tuesday, May 12, 2026 |
Globe Newswire |
05/05 |
07:00 |
